Tight Junction Protein 1 is a Modulator and Biomarker of Proteasome Inhibitor Sensitivity in Multiple Myeloma
收藏官方服务：
资源简介：
Tight Junction Protein 1 is a Modulator and Biomarker of Proteasome Inhibitor Sensitivity in Multiple Myeloma
应用场景：
创建时间：
2015-12-31
相关数据集
Postoperative Serum Levels of sCD26 for Surveillance in Colorectal Cancer Patients
One of the main aims of the follow-up after curative resection of colorectal cancer is the early detection and treatment of tumor recurrence. We previously demonstrated decreased preoperative soluble
Figshare2016-01-15 更新50
BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers. BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers
Expression data from patient-derived xenografts of human triple-negative breast cancers Overall design: We used GeneChip Human 1.1 ST arrays to identify the genes differentially expressed in PDX with
NIAID Data Ecosystem20
Patient characteristics (including Age at diagnosis, Binet stage, Rai stage, IgVH mutation status (um indicates unmutated, m mutated), genomic aberrations such as deletion 11q, deletion 13q14, deletion 17p, trisomy 12, ZAP70 status (pos indicates ZAP70 expression > 20%, neg indicates ZAP70 expression < 20%) (n.d. indicates not done, 1 indicates variable present, 0 indicates variable not present).
Patient characteristics (including Age at diagnosis, Binet stage, Rai stage, IgVH mutation status (um indicates unmutated, m mutated), genomic aberrations such as deletion 11q, deletion 13q14, deletio
NIAID Data Ecosystem20
Paleturquoise module genes.
Next-generation sequencing technology enables uniform and impartial assessment of cancer diagnoses and prognosis. However, such studies are mostly type-specific, and capturing shared genomic abnormali
Figshare2025-05-30 更新40
Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progression on therapy with irinotecan og cetuximab – effect and biological markers.
Main objective: • Disease control as the sum of number of patients with CR, PR and SD. Primary endpoints: Disease control as sum of number of patients with CR, PR, and SD
NIAID Data Ecosystem20
